

## Sensorion to Participate in Corporate Access Event in San Francisco, January 8 – 10, 2018

Montpellier, December 20, 2017 (06:00pm CET) – Sensorion (FR0012596468 – ALSEN / PEA-PME eligible), a biotech company pioneering novel treatments of inner ear diseases, today announced that its senior management team will host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.

To schedule a meeting with Sensorion, investors can <u>register</u> on the online system managed by the Company's US investor relations firm, <u>LifeSci Advisors, LLC</u>, or make a request via e-mail at <u>Access@LifeSciAdvisors.com</u>.

•••

## **About Sensorion**

Sensorion is a biotech company pioneering novel treatments of inner ear diseases such as severe vertigo, tinnitus or hearing loss. Two products are currently in the clinical development stage: SENS-111, in phase 2 in acute unilateral vestibulopathy (vestibular neuritis), and SENS-401, which has completed a phase 1 trial. The company was founded by Inserm (the French Institute of Health and Medical Research) and is utilizing its pharmaceutical R&D experience and comprehensive technology platform to develop first-in-class easy-to-administer, notably orally active, drugs for treating and preventing hearing loss and the symptoms of bouts of vertigo and tinnitus.

Based in Montpellier, Southern France, Sensorion has received financial support from Bpifrance, through the InnoBio fund, and Inserm Transfert Initiative.

Sensorion has been listed on the Euronext Growth Paris exchange since April 2015.

www.sensorion-pharma.com

## **Contacts**

**Sensorion** Nawal Ouzren Directeur général

contact@sensorion-pharma.com

Tél: 04 67 20 77 30

Libellé: **SENSORION** Code ISIN: **FR0012596468** Mnémonique: **ALSEN**  Tél: +41 79 367 6254

LifeSci Advisors LLC

chris@lifesciadvisors.com

Relations Presse Alize RP

Caroline Carmagnol & Wendy Rigal

Investor Relation - International

Chris Maggos - Directeur général, Europe

sensorion@alizerp.com



